Durability of Treatment with a Thermomechanical Device in Meibomian Gland Dysfunction: An Observational Extension Study
Journal of Ocular Pharmacology and Therapeutics · 2025
DOI: 10.1089/jop.2025.0033 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2025. Verfasst von Ehsan Sadri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Visionary Eye Institute, Newport Beach, California, USA. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Hyperthermia, Induced, Meibomian Gland Dysfunction, Meibomian Glands. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Purpose
To evaluate the durability of thermomechanical device treatment effect in patients with meibomian gland dysfunction (MGD) at 6 months post-treatment.
Methods
This was an extension of an initial 3-month, prospective, controlled, randomized, masked, multicenter pivotal study, in which subjects with MGD were randomized to thermomechanical device treatment (3 sessions, 2 weeks apart) or a single control treatment. The extension study was a single-arm, observational study in the same 5 sites of the pivotal study. A subset of subjects from the thermomechanical device group with an increase in tear break-up time (TBUT) of 2.5 s or greater in at least 1 eye at 1- or 3-month follow-up and able to attend the 6-month follow-up were included. Effectiveness endpoints included changes in TBUT, Meibomian gland score (MGS), and Ocular Surface Disease Index (OSDI) from baseline to 6 months. Device-related adverse events (AEs) were also assessed.
Results
At 6 months post-treatment, 21 subjects (42 eyes) demonstrated significant improvements from baseline in mean TBUT (5.2 ± 3.8 s; P < 0.001), mean MGS (18.2 ± 10.9; P < 0.0001), and mean OSDI (-24.3 ± 26.5; P = 0.0004). Improvements in corneal staining scores were also observed. No ocular AEs were reported.
Conclusions
The findings of the extension study demonstrate that the clinical benefit of the thermomechanical device, evaluated by TBUT, MGS, and OSDI, can be maintained out to 6 months and that the device is safe and effective in improving the signs and symptoms of evaporative dry eye disease in MGD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Visionary Eye Institute, Newport Beach, California, USA.
- Moyes Eye Center, PC, Kansas City, Missouri, USA.
- Parkhurst NuVision, San Antonio, Texas, USA.
- Anterior Segment and Refractive Surgery, Gordon Schanzlin New Vision Institute, La Jolla, California, USA.
- Novoxel Ltd, Netanya, Israel.
- Ophthalmology Associates, St. Louis, Missouri, USA.
ORCID-Profile: Gregg J Berdy
Zitieren
APA
Sadri, E., Verachtert, A., Parkhurst, G. D., Echegoyen, J., Klein, I., Agmon Gerstein, Y., & Berdy, G. J. (2025). Durability of Treatment with a Thermomechanical Device in Meibomian Gland Dysfunction: An Observational Extension Study. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2025.0033
Vancouver
Sadri E, Verachtert A, Parkhurst GD, Echegoyen J, Klein I, Agmon Gerstein Y, et al. Durability of Treatment with a Thermomechanical Device in Meibomian Gland Dysfunction: An Observational Extension Study. Journal of Ocular Pharmacology and Therapeutics. 2025. doi:10.1089/jop.2025.0033
BibTeX
@article{Sadri2025,
author = {Sadri, Ehsan and Verachtert, Anthony and Parkhurst, Gregory D and Echegoyen, Julio and Klein, Ifat and Agmon Gerstein, Yael and Berdy, Gregg J},
title = {Durability of Treatment with a Thermomechanical Device in Meibomian Gland Dysfunction: An Observational Extension Study},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2025},
doi = {10.1089/jop.2025.0033}
}
EUVIMED